Financial Data and Key Indicator Changes - The company achieved operating revenue of ¥9.109 billion, growing 17.7% year-over-year [5] - Total profit reached ¥2.119 billion, growing 83% year-over-year, while net profit was ¥1.758 billion, growing 78% year-over-year [5] - Non-GAAP net profit significantly increased by 170% year-over-year to ¥1.701 billion [5] - Net cash flow from operating activities was ¥1.441 billion, an increase of ¥1.214 billion year-over-year [5] - Total assets reached ¥53.7 billion, with the asset-liability ratio falling below 40% for the first time [5] Business Line Data and Key Indicator Changes - Yarn and electronic cloth sales volumes reached historical highs, with 1.5822 million tons of yarn sold, growing nearly 4% year-over-year, and 485 million meters of electronic cloth sold, growing 5.9% year-over-year [3] - The company focused on optimizing market structure and increasing the proportion of high-end products [2] Market Data and Key Indicator Changes - In the first half of the year, China's new wind power installed capacity was 51.39 million kilowatts, with year-over-year growth of 98.9% [1] - Automotive production in China reached 15.565 million vehicles, growing 10.8% year-over-year, with new energy vehicle production growing 36.2% [1] - The electronic information industry showed improvement, with microcomputer production reaching 166 million units, growing 5.6% year-over-year [1] Company Strategy and Development Direction - The company aims to adhere to a dual-wheel drive of volume increase and price enhancement, focusing on market competitive advantages and marketing strategies [1] - The strategic focus includes sales priority, efficiency improvement, innovation-driven development, quality requirements, system construction, and effective team culture [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving annual targets and emphasized the importance of maintaining stable sales volume and price targets [7] - The company is optimistic about the overall market recovery and expects steady growth in the second half of the year [27] Other Important Information - The company has released ESG reports for five consecutive years, with improved ratings [5] - Interim dividends of ¥680 million were planned, with a dividend ratio exceeding 40% [6] Q&A Session Summary Question: Outlook on coarse sand segment and pricing strategy - Management noted that the supply and demand situation for coarse sand is stable, with a focus on controlling capacity and stabilizing prices [10][12] Question: Future price fluctuation range for coarse sand - Management indicated that achieving a net profit of around ¥900 to ¥1,000 per ton is ideal, while reaching ¥2,000 per ton would be considered abnormal [23][24] Question: Plans for overseas production expansion - Management confirmed that the U.S. factory has turned profitable and that there are plans for further overseas expansion, with a focus on Southeast Asia, Africa, and Europe [26][27] Question: Adjustments to pricing strategy in response to high-end product demand uncertainty - Management stated that they will monitor market conditions and adjust pricing strategies as necessary, particularly in response to high-end product demand fluctuations [48][49]

Financial Data and Key Indicator Changes - The company achieved operating revenue of ¥9.109 billion, growing 17.7% year-over-year [5] - Total profit reached ¥2.119 billion, growing 83% year-over-year, while net profit was ¥1.758 billion, growing 78% year-over-year [5] - Non-GAAP net profit significantly increased by 170% year-over-year to ¥1.701 billion [5] - Net cash flow from operating activities was ¥1.441 billion, an increase of ¥1.214 billion year-over-year [5] - Total assets reached ¥53.7 billion, with the asset-liability ratio falling below 40% for the first time [5] Business Line Data and Key Indicator Changes - Yarn and electronic cloth sales volumes reached historical highs, with 1.5822 million tons of yarn sold, growing nearly 4% year-over-year, and 485 million meters of electronic cloth sold, growing 5.9% year-over-year [3] - The company focused on optimizing market structure and increasing the proportion of high-end products [2] Market Data and Key Indicator Changes - The overall market supply and demand situation showed significant improvement, with glass fiber yarn output growth of approximately 4.9% year-over-year [1] - In the renewable energy sector, China's new wind power installed capacity grew by 98.9% year-over-year [1] - Automotive production in China increased by 10.8% year-over-year, with new energy vehicle production growing by 36.2% [1] - The electronic information industry saw a 5.6% year-over-year growth in microcomputer production [1] Company Strategy and Development Direction - The company is focusing on dual-wheel drive of volume increase and price enhancement, strengthening market competitive advantages [1] - Emphasis on innovation and R&D, with first-half R&D investment of ¥280 million, up 10.73% year-over-year [4] - The company plans to implement interim dividends for the first time, with a dividend amount of ¥680 million and a dividend ratio exceeding 40% [7] - Future focus includes maintaining sales volume and price targets, improving efficiency, and adhering to innovation-driven development [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving annual targets and completing the 14th Five-Year Plan [7] - The company anticipates stable growth in export markets in the second half of the year, despite a 1.9% decline in volume in the first half [27] - Management noted that the anti-involution policy may lead to more rational capacity deployment in the industry [16] Other Important Information - The company has been recognized for its ESG efforts, with improved ratings from MSCI and Wind [5] - The company is actively planning overseas expansion, with a focus on balancing domestic and international capacity growth [27] Q&A Session Summary Question: Outlook on coarse sand segment and pricing strategy - Management noted that the overall new capacity added was substantial, and they are cautiously controlling capacity release [12] - Future pricing is expected to remain stable with some increases, particularly in mid-to-high-end products [15] Question: Future price fluctuation range for coarse sand - Management indicated that achieving a net profit of around ¥2,000 per ton would be abnormal under current conditions [24] Question: Plans for overseas production expansion - The company is exploring opportunities in Southeast Asia, Africa, and Europe, with a balanced approach to domestic and international capacity growth [27] Question: Impact of tariffs and anti-dumping investigations - Management stated that they are monitoring the situation and adjusting strategies accordingly to mitigate risks [48] Question: Demand for high-end products and pricing strategy adjustments - Management acknowledged potential uncertainties in high-end product demand but emphasized ongoing adjustments to pricing strategies based on market conditions [49]

Financial Data and Key Metrics Changes - The company reported a Q2 EBITDA that was 19% higher than the same quarter last year, and H1 EBITDA was nearly 20% above H1 last year, marking the fifth consecutive quarter of EBITDA growth [9][10] - Gross margin improved from 26.8% to 29.6%, and EBITDA margin increased from 10.8% to 13.3% compared to the same period last year [11] - Free cash flow increased by $24 million to a total of $32 million, reflecting strong cash management [15][32] Business Line Data and Key Metrics Changes - The company achieved a top-line sales increase for the first time since Q3 2022, reaching $908 million, driven by a 6% volume growth that offset a 3% decline in prices [17] - Gross profit increased by 14%, with a gross margin of 29% in Q2 2025 compared to 26% in Q2 2024 [17][21] - EBITDA for H1 2025 reached $244 million, a 20% increase compared to the previous year [21] Market Data and Key Metrics Changes - Sales in North America grew by approximately 20%, benefiting from a rebound in market volumes [25] - Sales in Europe, Africa, and the Middle East showed a slight drop, but would have grown by 3% if not for geopolitical issues in Turkey [24] - The company faced significant price pressure in Latin America, particularly in Brazil and Argentina, impacting overall performance in that region [28] Company Strategy and Development Direction - The company is focused on a transformation strategy called "Fight Forward," aimed at improving profitability and growing the top line by focusing on high-margin products [12][59] - The management emphasized the importance of operational efficiency and cost reduction initiatives that have contributed to improved margins [12][19] - The company aims to leverage its differentiated product portfolio to gain market share in key regions moving forward [59] Management's Comments on Operating Environment and Future Outlook - Management noted that the agrochemical market remains in an oversupply situation, primarily due to overcapacity from China, which continues to exert price pressure [5][6] - Despite challenges, there are signs of market stabilization, with normalized inventory levels leading to improved volume dynamics [46][48] - The management expressed confidence in the company's ability to navigate the current environment and capitalize on growth opportunities [59][60] Other Important Information - The company has undergone significant restructuring, which has resulted in a narrowing of net profit losses, with reported net profit at $43 million in Q2 2025, down 64% from the previous year [19][22] - The company has a net debt to EBITDA ratio of 2.5, which is within the required covenant limits [34] Q&A Session Summary Question: What are the main challenges faced in the market? - Management highlighted ongoing price pressures due to farmer profitability issues and geopolitical factors affecting sales in certain regions [47][48] Question: How is the company addressing operational efficiency? - The company has implemented various initiatives under the "Fight Forward" plan to reduce costs and improve operational efficiency, contributing to better margins [12][19] Question: What is the outlook for growth in key markets? - Management expressed optimism about growth opportunities in North America and Europe, while acknowledging challenges in Latin America and India [25][28]

Financial Data and Key Metrics Changes - The company reported a Q2 EBITDA of $180 million, which is 19% higher than the same quarter last year, and H1 EBITDA was nearly 20% above H1 last year [9][18] - Gross margin improved from 26.8% to 29.6%, and EBITDA margin increased from 10.8% to 13.3% [11] - Free cash flow increased by $24 million to a total of $32 million [15][30] Business Line Data and Key Metrics Changes - The company achieved a top-line sales increase for the first time since Q3 2022, reaching $906 million, driven by a 6% volume growth that offset a 3% price decline [17] - Gross profit increased by 14%, with a gross margin of 29% in Q2 2025 compared to 26% in Q2 2024 [17][20] Market Data and Key Metrics Changes - Sales in North America grew by approximately 20%, benefiting from a rebound in market volumes [24] - Sales in Europe, Africa, and the Middle East showed a slight drop, but would have grown by 3% if not for geopolitical issues in Turkey [22] - Latin America experienced a drop in sales primarily due to significant price pressure in Brazil and Argentina [26] Company Strategy and Development Direction - The company is focused on a transformation strategy called "Fight Forward," aimed at improving profitability and then growing the top line [13][56] - The management emphasized the importance of focusing on high-margin products and exiting low-profit segments [20][22] Management's Comments on Operating Environment and Future Outlook - Management noted that the agrochemical market remains in an oversupply situation, primarily due to overcapacity from China, which continues to exert price pressure [5][6] - There are signs of market stabilization, with normalized channel inventories and a shift towards more strategic conversations with customers [43][46] Other Important Information - The company has a net debt to EBITDA ratio of 2.5, which is within the required covenant limits [32] - The management highlighted the importance of cash flow management and operational efficiency as key components of their strategy [15][30] Q&A Session Summary Question: What are the main challenges faced in the Turkish market? - The company faced significant sales losses in Turkey due to geopolitical issues and restrictions imposed by the Turkish government [19] Question: How is the company addressing pricing pressures? - Management acknowledged ongoing pricing pressures due to farmer profitability issues and overcapacity in the market, but emphasized their focus on operational efficiencies to mitigate these impacts [6][46]

Financial Data and Key Metrics Changes - The company reported a revenue of RMB 950 million for the first half of 2025, with over RMB 300 million coming from commercialized drugs, marking a significant achievement in its first year of commercialization [50][51] - Gross profit was RMB 660 million, comparable to the previous year, while the net loss for the first half was RMB 145 million, with an adjusted loss of RMB 69 million after one-off budget adjustments [52][53] - The company has a healthy financial status with cash and financial assets totaling RMB 4.5 billion and debts less than RMB 1 billion [56] Business Line Data and Key Metrics Changes - The company has three main products ready for the market, with significant progress in approvals and commercialization efforts [12][28] - The commercialization team has expanded to nearly 400 personnel to support the growing number of products [12] - The company has successfully partnered with over 400 pharmacies and covered over 1,000 hospitals across China [28][32] Market Data and Key Metrics Changes - The company has achieved coverage in 30 provinces and 300 cities, with over 10,000 doctors engaged [28] - The company is actively working on gaining medical insurance coverage for its products, with seven provinces already covered under specific affordable care programs [33][34] Company Strategy and Development Direction - The company aims to advance differentiated pipelines targeting significant medical needs and optimize payload linker strategies with novel ADC designs [26] - The focus is on expanding global partnerships and enhancing drug development and commercialization capabilities [26] - The company is committed to exploring applications in non-oncology areas while maintaining a strong emphasis on oncology [19][26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future income from sales revenue, anticipating continued cash flow generation from both R&D partnerships and commercialized drugs [51] - The company is preparing for a significant increase in sales volume once products are included in the medical insurance catalog [94] - Management acknowledged the importance of educating clinical experts on ADC drugs to facilitate market adoption [65] Other Important Information - The company completed a follow-on financing of USD 250 million and is now included in several global equity indexes [25] - The company has initiated multiple pivotal trials globally, including for TNBC and HR-positive breast cancer [21][22] Q&A Session Summary Question: What is the breakdown of sales revenue for breast cancer and lung cancer? - Lung cancer is the biggest contributor to sales revenue, consistent with patient numbers and indications [62] Question: What is the company's sales expenses ratio going into medical insurance coverage next year? - Sales expenses are currently high due to the first year of commercialization, but costs are expected to decrease once products are included in the medical insurance catalog [63] Question: What is the focus for R&D going into the next stage? - The focus is on developing differentiated products targeting clinical demands, with an emphasis on bispecific targets and new payload strategies [68][70] Question: Can you provide guidelines on the sales trend for Q3? - The company expects quarter-over-quarter growth, with significant sales anticipated in the second half of the year [74] Question: What is the rationale behind the clinical trial design for PD L1 positive and negative patients? - The company is focusing on both PD L1 positive and negative patients to ensure comprehensive treatment coverage [89] Question: How is the company addressing IP disputes? - The company has initiated a lawsuit against several founders related to IP disputes, which is currently under review by the Sichuan Provincial High Court [101]

Financial Data and Key Metrics Changes - The company reported a revenue of RMB 950 million for the first half of 2025, with over RMB 300 million coming from commercialized drugs, marking a significant achievement in its first year of commercialization [52][53] - Gross profit was RMB 660 million, comparable to the previous year, while the net loss for the first half was RMB 145 million, with an adjusted loss of RMB 69 million after one-off budget adjustments [54][55] - Cash and financial assets totaled RMB 4.5 billion, indicating a healthy financial status to support upcoming R&D and innovation [58] Business Line Data and Key Metrics Changes - The company has three main products ready for the market, with significant progress in approvals and commercialization efforts [15][32] - The commercialization team has expanded to nearly 400 personnel to support the increasing number of products ready for market [14] Market Data and Key Metrics Changes - The company has successfully covered over 30 provinces, 300 cities, and 1,000 hospitals across China, with partnerships established with over 400 pharmacies [32][34] - The company is actively working towards gaining medical insurance coverage for its products, which is expected to enhance market access and sales [36][81] Company Strategy and Development Direction - The company aims to advance differentiated pipelines targeting significant medical needs, optimizing payload linker strategies, and exploring applications in non-oncology areas [30] - The focus is on expanding global partnerships and strengthening strategic collaborations to maximize the value of its pipelines [30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future income from sales revenue, anticipating continued cash flow generation from commercialized drugs [53] - The company is preparing for the implementation of new medical insurance policies, which are expected to impact product sales positively [100] Other Important Information - The company completed a follow-on financing of USD 250 million and is included in major global equity indexes, enhancing its market presence [29] - The company has initiated several pivotal trials globally, including for various cancer indications, which are expected to drive future growth [25][26] Q&A Session Summary Question: What is the breakdown of sales revenue for breast cancer and lung cancer? - Lung cancer is the biggest contributor to sales revenue, consistent with patient numbers and indications [64] Question: What is the focus for R&D going into the next stage? - The focus is on developing differentiated products targeting clinical demands, with an emphasis on bispecific targets and new payload strategies [70][72] Question: Can you provide guidelines on the sales trend for Q3? - The company expects quarter-over-quarter growth, with significant sales anticipated from lung cancer indications [76] Question: What is the strategy for going into the medical insurance catalog? - The strategy prioritizes entering the medical insurance catalog to enhance market access and sales volume [100] Question: Can you address the IP disputes mentioned? - The company has initiated a lawsuit against several founders related to IP disputes, which is currently under review by the Sichuan Provincial High Court [103]

Financial Data and Key Indicators Changes - In 2024, the company's revenue increased by 0.66% year on year, while net profit grew by 0.12% year on year, achieving dual growth [4] - The growth in net profit was primarily due to reductions in risk costs and operating expenses, with impairment provisions and business management fees decreasing by 1.62% and 0.65% respectively [5] - The total assets surpassed RMB 10.5 trillion, with over 70,000 employees and more than 200 operational institutions [15] Business Line Data and Key Indicators Changes - The total number of retail clients reached 110 million, and corporate clients totaled 1.54 million, representing a 9.7% increase compared to the end of 2023 [6] - Wealth management retained a strong market position, with public fund AUM reaching RMB 347.5 billion, up 32.7%, and industrial trust AUM totaling RMB 4 billion, an increase of 118% [7] - The corporate banking closed-loop transaction number was USD 2.3 billion, up by 16% [24] Market Data and Key Indicators Changes - The deposit interest payment rate decreased to 1.98%, down 26 basis points, while the corporate deposit interest payment rate was 1.93%, down by 30 basis points [6] - The low-cost interbank exceeded RMB 800 billion, marking a 20% increase [6] - The company anticipates a further decline in the deposit interest ratio by 24 basis points in 2025 [25] Company Strategy and Development Direction - The company aims to enhance its digital transformation and operational efficiency, focusing on technology finance and aligning with national financial reforms [3][4] - The strategy includes building a wealth management and asset management working team to enhance coordination and drive revenue growth [13] - The company is committed to becoming a value-driven bank, emphasizing strong profitability, deep client collaboration, and low risk costs [4] Management's Comments on Operating Environment and Future Outlook - The management acknowledged the challenges posed by the current economic environment, including weak demand and corporate solvency issues, but expressed confidence in outperforming the market [28][30] - The management highlighted the importance of adapting to changes in the real estate sector and maintaining a balanced approach to risk management [20][22] - The company is focused on enhancing its retail banking business and expects to achieve greater results over the next three years [70] Other Important Information - The company has established a digital operation center to improve client service capabilities and enhance precision marketing [8] - The management emphasized the importance of standardization in data and operational processes to improve efficiency [49][50] - The dividend payout ratio surpassed 30% last year, reflecting the company's commitment to providing returns to investors [73] Q&A Session Summary Question: What is the outlook for technology finance loans and credit loan placement in 2025? - The management highlighted that technology finance loans have surpassed RMB 960 billion with a low NPL ratio of 0.77%, indicating strong growth potential [34] - The company plans to focus on qualitative improvements in credit loan placement, with an emphasis on green finance and inclusive finance [34] Question: How will the company approach AI empowerment in the future? - The Chief Information Officer stated that the company is actively deploying AI strategies to enhance financial innovation and improve service capabilities [60][64] Question: Will the company maintain its dividend payout ratio trend? - The Chairman confirmed that the company is committed to sustaining a dividend payout ratio above 30% and aims to grow together with investors [73]

Financial Data and Key Indicators Changes - The operating income for 2024 is RMB 728.6 billion, with a net profit of RMB 336.3 billion, reflecting a year-on-year increase of 1.15% in ROE [6][27] - The NPL ratio decreased by 0.03 percentage points to 1.34%, with a capital adequacy ratio of 19.69% and a cost-to-income ratio of 29.58% [6][35] - The net interest margin (NIM) is reported at 1.51%, leading the industry [6][47] Business Line Data and Key Indicators Changes - Loans to strategic emerging industries exceeded RMB 3.5 trillion, with green loans reaching RMB 4.7 trillion, showing significant growth from the previous year [7][8] - The balance of inclusive finance loans is RMB 3.41 trillion, maintaining a leading position in the market [8][40] - Personal loans, including mortgage loans, saw a growth rate of 25%, with the balance of personal housing loans at RMB 1.19 trillion [30][76] Market Data and Key Indicators Changes - The total assets of the bank reached RMB 40 trillion, with a daily balance of RMB 39 trillion, up by 8% year-on-year [28][33] - The bank's corporate customer base surpassed 11 million, with individual customers reaching 700 million [33][40] - The bank remains the largest RMB clearing bank outside Asia, enhancing its position in cross-border financial services [11] Company Strategy and Development Direction - The company aims to enhance its financial services in five main areas, focusing on technology, green finance, elderly care finance, and supporting the real economy [16][21] - The bank plans to optimize its asset structure and enhance its revenue from non-interest income, targeting a stable growth of loans [18][36] - The company is committed to supporting the national strategy to boost consumption and improve customer experience through digital finance [19][22] Management's Comments on Operating Environment and Future Outlook - Management noted that 2024 has shown progress amid stability, overcoming challenges posed by lower interest rates [27][28] - The bank is confident in maintaining stable asset quality and is prepared to address risks, especially in the real estate sector [57][58] - The outlook for 2025 includes a focus on high-quality development and enhancing the integration of services with customer ecosystems [22][92] Other Important Information - The bank achieved a AAA rating, becoming the first Chinese mainland bank to receive such a rating, reflecting its strong commitment to ESG principles [8][83] - The bank's non-interest income for 2024 was RMB 138.7 billion, an increase of 8% year-on-year, with significant contributions from wealth management and consumer finance [69][72] Q&A Session Summary Question: What is the driving force behind the performance? - Management highlighted progress amid stability, with higher net profit and market-leading indicators despite lower interest rates [27][28] Question: Can you specify which sectors the loan services are targeted at? - The bank supports various sectors, including technology, green energy, and manufacturing, with a focus on high-tech companies and infrastructure projects [40][43] Question: What measures are in place to maintain asset quality? - The bank has implemented a robust risk control system, maintaining a low NPL ratio and enhancing early warning systems for risk management [55][81] Question: How will the bank approach the bond market in 2025? - The bank plans to enhance its role as a main underwriter for local and treasury bonds, focusing on infrastructure and policy-driven projects [61][63] Question: What are the plans for ESG initiatives moving forward? - The bank aims to integrate ESG principles into its operations, focusing on governance, environmental impact, and social responsibility [84][91]

Financial Data and Key Metrics Changes - In Q4 2024, gross profit increased by 14% and EBITDA rose by 45% compared to the same period last year [10][11] - Full year EBITDA for 2024 was 15% higher than 2023, marking one of the few companies in the industry to show growth in EBITDA [10][11] - Sales for Q4 2024 decreased by 2% to $1.1 billion, but at constant exchange rates (CER), they increased by 2% [15] - Full year sales declined by 11% to $4.1 billion, with an 8% decrease in CER [17][19] - The company achieved a gross margin of 25.6% in 2024, up from 22.7% in 2023 [18][19] Business Line Data and Key Metrics Changes - The company experienced a significant improvement in gross profit and EBITDA margins due to better cost management and a favorable product mix [15][19] - The sales volume remained stable, but pricing pressures led to an overall decline in sales [17][19] Market Data and Key Metrics Changes - In North America, the company saw a growth in sales despite a declining market, attributed to strategic deals with major distributors [68][69] - Latin America experienced a 4% increase in local currency sales, but an 8% decline in dollar terms due to currency impacts [22][26] - Asia Pacific saw a decline of 6-7% in sales, influenced by strategic decisions to align sales closer to the agricultural season [22][23] Company Strategy and Development Direction - The company is focused on a "Fight Forward" transformation plan aimed at improving financial health and operational efficiency [34][36] - The strategy includes centralizing corporate functions, optimizing geographical presence, and focusing on high-value products while exiting low-profit markets [41][42][43] - The company aims to enhance its competitive position in the value innovation segment, targeting growers seeking innovation at acceptable prices [47][48] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing pressure on grower profitability and overcapacity in the market, particularly from Chinese producers [7][8] - Despite challenges, the company is optimistic about maintaining momentum into 2025, supported by improved performance metrics in Q4 2024 [75] - The management emphasized the importance of strategic decisions to walk away from low-profit products to focus on value innovation [72][73] Other Important Information - The company reduced its inventory significantly, from $2.4 billion at the end of 2022 to $1.05 billion in 2024, reflecting efficient inventory management [32] - Operating cash flow improved to $528 million, with free cash flow reaching $364 million, higher than the previous year [30][31] Q&A Session Summary Question: Recent price trends of pesticides and market demand - Management indicated that while some active ingredients have seen price increases, the majority remain at historical lows due to overproduction [60][63] Question: Stability of NPI rate and performance of differentiated products - The stable NPI rate reflects ongoing R&D investment, with improvements in sales of differentiated products noted in Q4 [64][65][66] Question: Regional sales performance and North America outlook - Management clarified that while overall sales declined, North America saw growth due to strategic partnerships, maintaining market share [68][69] Question: Impact of Bayer's potential withdrawal from glyphosate market - Management refrained from commenting on competitors but reiterated their strategic focus on high-value products [72] Question: Potential rebound in sales and profits for 2025 - Management did not provide specific guidance but expressed optimism based on Q4 performance improvements [75] Question: Effectiveness of the Fight Forward plan amid rising expenses - Management explained that increased expenses are due to one-time costs related to restructuring and transformation initiatives [76][77] Question: Future business outlook amid U.S. tariff increases - Management acknowledged the challenges posed by tariffs but emphasized the company's diversified production footprint as a mitigating factor [78][84] Question: Implementation of the one product or one registration policy in China - Management is preparing for the policy's implementation, expecting opportunities for growth through differentiated product innovation [86][87] Question: Guidance on short and mid-term targets for expense reduction - Management reiterated that they do not provide guidance but are focused on optimizing operational costs [88] Question: Status of management structure adjustments - Management confirmed that the transformation process is ongoing, with a focus on enhancing competitive strategies and KPIs [89][90]

Financial Data and Key Indicator Changes - In 2024, Ping An Bank achieved operating income of RMB 44.2 billion, down 10.9% year on year [5][23] - The net profit for the year was RMB 44.5 billion, reflecting a decrease but maintaining a strong provision coverage ratio of 251% [7][23] - Total assets increased steadily, with retail deposits rising by 3.7% compared to the beginning of the year [22][24] Business Line Data and Key Indicator Changes - Corporate Banking saw total assets increase by 3.3% and corporate loan balance grow by 12.4%, while personal loans decreased by nearly 11% due to a proactive reduction of high-risk businesses [6][27] - The proportion of mortgage-based loans increased by 4%, reaching 62.8% [7] - Retail Banking is undergoing restructuring, focusing on medium-risk products and customer-centric services [78][79] Market Data and Key Indicator Changes - The banking sector is experiencing a turning point from scale expansion to quality development, with net interest margins under pressure [2][3] - The overall market environment remains challenging, with increasing competition and pressure on net interest margins expected in 2025 [72] Company Strategy and Development Direction - The company is committed to strengthening retail banking while refining corporate banking and interbank business, focusing on high-quality growth and risk management [9][12] - Ping An Bank aims to leverage technology and fintech to enhance service delivery and operational efficiency [8][12] - The strategic direction includes a balanced approach to business growth, integrating risk management and customer relationship management [14][15] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges posed by the current economic environment but expresses confidence in the bank's ability to adapt and grow [19][72] - The focus will be on improving asset quality and reducing non-performing loans (NPLs), with expectations for a positive growth trajectory in retail loans by 2025 [91][92] - The bank plans to maintain a reasonable dividend level while balancing capital needs and shareholder returns [94][96] Other Important Information - The bank has implemented major initiatives in technology, green finance, and inclusive finance to support high-quality development [8][23] - Ping An Bank's core Tier 1 capital adequacy ratio remains robust despite a slight decrease [24][96] Q&A Session Summary Question: How will the adjustment affect the positioning and strategy of the Retail business? - Management has streamlined the retail strategy, focusing on risk management and reducing dependency on high-risk products [39][41] Question: What are the driving factors behind the reduction in NIM? - Factors include interest rate reductions and adjustments in high-risk loans, with expectations for further improvements in 2025 [51][53] Question: What is the outlook for retail asset quality and NPL trends? - The NPL ratio for retail assets is expected to improve, with management confident in a positive growth trajectory for retail loans in 2025 [88][91] Question: What is the reason for the decrease in dividend rates? - The decrease is attributed to capital pressures, but management aims to maintain a balanced approach to shareholder returns [94][96] Question: How is the bank evaluating the property market and its impact on asset quality? - Management believes the property market is stabilizing due to government support, which should positively impact asset quality moving forward [104]